Found: 321
Select item for more details and to access through your institution.
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 7, p. 1076, doi. 10.2967/jnumed.123.267004
- By:
- Publication type:
- Article
DosePatch: physics-inspired cropping layout for patch-based Monte Carlo simulations to provide fast and accurate internal dosimetry.
- Published in:
- EJNMMI Physics, 2024, v. 11, n. 1, p. 1, doi. 10.1186/s40658-024-00646-y
- By:
- Publication type:
- Article
Safety and Efficacy of Extended Therapy with [<sup>177</sup>Lu]Lu-PSMA: A German Multicenter Study.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 6, p. 909, doi. 10.2967/jnumed.123.267321
- By:
- Publication type:
- Article
RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 6, p. 917, doi. 10.2967/jnumed.123.267234
- By:
- Publication type:
- Article
Differences and Common Ground in <sup>177</sup>Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 3, p. 438, doi. 10.2967/jnumed.123.266391
- By:
- Publication type:
- Article
Preclinical comparison of [<sup>177</sup>Lu]Lu-rhPSMA-10.1 and [<sup>177</sup>Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2024, v. 9, n. 1, p. 1, doi. 10.1186/s41181-024-00246-2
- By:
- Publication type:
- Article
Differences and Common Ground in <sup>177</sup>Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 2, p. 1, doi. 10.2967/jnumed.123.266391
- By:
- Publication type:
- Article
Current status of PSMA-targeted imaging and therapy.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1230251
- By:
- Publication type:
- Article
Renal and Multiorgan Safety of <sup>177</sup>Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 1, p. 71, doi. 10.2967/jnumed.123.265448
- By:
- Publication type:
- Article
Long-Term Nephrotoxicity of <sup>177</sup>Lu-PSMA Radioligand Therapy.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 1, p. 79, doi. 10.2967/jnumed.123.265986
- By:
- Publication type:
- Article
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 1, p. 94, doi. 10.2967/jnumed.123.266164
- By:
- Publication type:
- Article
How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 51, n. 1, p. 3, doi. 10.1007/s00259-023-06389-9
- By:
- Publication type:
- Article
Comparative Analysis of Morphological and Functional Effects of 225 Ac- and 177 Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 23, p. 16845, doi. 10.3390/ijms242316845
- By:
- Publication type:
- Article
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior <sup>223</sup>Ra (RALU Study).
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1925, doi. 10.2967/jnumed.123.266125
- By:
- Publication type:
- Article
SNMMI Procedure Standard/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases.
- Published in:
- Journal of Nuclear Medicine Technology, 2023, v. 51, n. 4, p. 1, doi. 10.2967/jnmt.123.265936
- By:
- Publication type:
- Article
Prevalence of bilateral loco-regional spread in unilateral pelvic PSMA PET positive recurrent prostate cancer.
- Published in:
- Minerva Urology & Nephrology, 2023, v. 75, n. 6, p. 734, doi. 10.23736/S2724-6051.23.05445-9
- By:
- Publication type:
- Article
Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer.
- Published in:
- EJNMMI Research, 2023, v. 13, n. 1, p. 1, doi. 10.1186/s13550-023-01044-8
- By:
- Publication type:
- Article
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of <sup>177</sup>Lu-PSMA I&T.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 11, p. 1765, doi. 10.2967/jnumed.123.265878
- By:
- Publication type:
- Article
EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 5008, doi. 10.3390/cancers15205008
- By:
- Publication type:
- Article
A randomised trial of [<sup>18</sup>F]PSMA‐1007‐PET/CT versus NaF‐PET/CT for staging primary prostate cancer: A trial protocol.
- Published in:
- BJUI Compass, 2023, v. 4, n. 5, p. 513, doi. 10.1002/bco2.243
- By:
- Publication type:
- Article
SNMMI Procedure Standard/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases.
- Published in:
- Journal of Nuclear Medicine Technology, 2023, v. 51, n. 3, p. 176, doi. 10.2967/jnmt.123.265936
- By:
- Publication type:
- Article
Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support.
- Published in:
- World Journal of Urology, 2023, v. 41, n. 9, p. 2343, doi. 10.1007/s00345-023-04534-5
- By:
- Publication type:
- Article
Development and external validation of a multivariable [<sup>68</sup>Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3137, doi. 10.1007/s00259-023-06278-1
- By:
- Publication type:
- Article
Safety and Efficacy of [<sup>177</sup>Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1244, doi. 10.2967/jnumed.122.265259
- By:
- Publication type:
- Article
The Impact of PSMA PET--Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen--Targeted Radioligand Therapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1252, doi. 10.2967/jnumed.122.265346
- By:
- Publication type:
- Article
PSMA Is Not Specific to Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1326, doi. 10.2967/jnumed.123.265921
- By:
- Publication type:
- Article
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT).
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 9, p. 2830, doi. 10.1007/s00259-023-06255-8
- By:
- Publication type:
- Article
Neue Tracer und Kombinationen bei der Radioligandentherapie des Prostatakarzinoms.
- Published in:
- Die Urologie, 2023, v. 62, n. 7, p. 691, doi. 10.1007/s00120-023-02125-1
- By:
- Publication type:
- Article
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 7, p. 1024, doi. 10.2967/jnumed.122.265242
- By:
- Publication type:
- Article
Delayed Imaging Improves Lesion Detectability in [<sup>99</sup>mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 7, p. 1036, doi. 10.2967/jnumed.122.265252
- By:
- Publication type:
- Article
Adoption of Lutetium-<sup>177</sup> PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 7, p. 2188, doi. 10.1007/s00259-023-06139-x
- By:
- Publication type:
- Article
Prognostic Role of <sup>68</sup>Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 6, p. 896, doi. 10.2967/jnumed.122.264962
- By:
- Publication type:
- Article
What Is Theranostics?
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 5, p. 669, doi. 10.2967/jnumed.123.265670
- By:
- Publication type:
- Article
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 5, p. 685, doi. 10.2967/jnumed.122.265353
- By:
- Publication type:
- Article
Is there more than meets the eye in PSMA imaging in prostate cancer with PET/MRI? Looking closer at uptake time, correlation with PSA and Gleason score.
- Published in:
- European Journal of Hybrid Imaging, 2023, v. 7, n. 1, p. 1, doi. 10.1186/s41824-023-00166-5
- By:
- Publication type:
- Article
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 5, p. 1466, doi. 10.1007/s00259-022-06089-w
- By:
- Publication type:
- Article
Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU Study.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 4, p. 574, doi. 10.2967/jnumed.122.264456
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 3, p. 402, doi. 10.2967/jnumed.122.264402
- By:
- Publication type:
- Article
Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1809, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study.
- Published in:
- Cancers, 2022, v. 14, n. 22, p. 5680, doi. 10.3390/cancers14225680
- By:
- Publication type:
- Article
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 11, p. 1651, doi. 10.2967/jnumed.121.263072
- By:
- Publication type:
- Article
Temporary Reactive Response of Axillary Lymph Nodes to COVID-19 Vaccination on <sup>18</sup>F-rhPSMA-7.3 PET/CT in Patients with Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 11, p. 1673, doi. 10.2967/jnumed.121.263758
- By:
- Publication type:
- Article
Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with <sup>177</sup>Lu-PSMA I&T therapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 12, p. 4064, doi. 10.1007/s00259-022-05883-w
- By:
- Publication type:
- Article
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 12, p. 4271, doi. 10.1007/s00259-022-05882-x
- By:
- Publication type:
- Article
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263072
- By:
- Publication type:
- Article
Tumor Sink effect: Myth or Reality?.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264119
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
<sup>177</sup>Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264402
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article